← Eichor
Study identifier: NCT05865119 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

OPTImal Treatment of Sinus VENOSUS Defect

Condition: Sinus Venosus Defect · Congenital Heart Disease · Sinus Venosus Atrial Septum Defect  ·  Sponsor: Centre Chirurgical Marie Lannelongue

PhaseNA
Planned participants60
Who can joinAll sexes, 12 Years to no upper limit
Healthy volunteersNo

About this study

Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option. The procedure involves placement of a covered stent in the superior vena cava that tunnels the anomalous pulmonary venous return to the left atrium. Preliminary results are limited but promising. The devices to be used depend on anatomic considerations. XXL stents than 70mm are often required. Today, the availability of CE marked stents is limited. There have been recent reports of successful corrections with the specifically developed Optimus XXL 100mm covered stent (ANDRATEC) with compassionate approval from the Agence Nationale de Sûreté du Médicament in France. Setting up a feasibility study to investigate the use of medical devices in this indication was required. The objective of this project is to study the feasibility, efficacy and safety of the Optimus stent in this newly developed transcatheter procedure, in comparison with the gold-standard surgical method. A French national multicenter comparative cohort study including all eligible patients referred for transcatheter correction of SVD was designed. The feasibility of the transcatheter procedures will be investigated beforehand by virtual digital simulation and simulation on a 3D printed model. The …

This description comes directly from the study's public registry record.

Talk to the study team

SEBASTIEN HASCOËT  ·  +33140942429  ·  s.hascoet@ghpsj.fr

FLORENCE LECERF  ·  +33140942517  ·  f.lecerf@ghpsj.fr

Always discuss trial participation with your own doctor first.

Locations (13)

CHU BordeauxBordeaux, FranceNot Yet Recruiting
Hospices Civils de LyonBron, FranceNot Yet Recruiting
CHU Clermont-FerrandClermont-Ferrand, FranceNot Yet Recruiting
CHU GrenobleGrenoble, FranceRecruiting
Sébastien HASCOËTLe Plessis-Robinson, FranceRecruiting
CHU LilleLille, FranceRecruiting
Hôpitaux universitaire de MarseilleMarseille, FranceNot Yet Recruiting
CHU NantesNantes, FranceNot Yet Recruiting
CHU Necker APHP ParisParis, FranceNot Yet Recruiting
HEGP ParisParis, FranceNot Yet Recruiting
CHU ToulouseToulouse, FranceNot Yet Recruiting
Clinique Pasteur, ToulouseToulouse, FranceNot Yet Recruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05865119